echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Waiting for 23 years of breakthrough!

    Waiting for 23 years of breakthrough!

    • Last Update: 2021-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, AstraZeneca and Sanofi jointly announced that the research antibody nirsevimab has reached the primary endpoint in a phase 3 clinical trial, successfully preventing respiratory syncytial virus (RSV) infection in infants.


    Respiratory syncytial virus is a very common infectious pathogen that can cause seasonal epidemics of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia.


    Nirsevimab is a long-acting antibody, jointly developed by AstraZeneca and Sanofi, which can directly provide immunity to infants and provide immediate protection against RSV.


    In the phase 3 clinical trial, nirsevimab reached the primary endpoint.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.